The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2019-2020 flu season, around 25,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses.

Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 7.4 per 100,000 population during the 2021-2022 flu season. In comparison, the mortality rate for those aged 50 to 64 years was just 1.2 per 100,000 population.

Flu vaccinations The most effective way to prevent influenza is to receive a yearly influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2021-2022 flu season only 37 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2021-2022 flu season vaccinations prevented over 618 thousand influenza cases among children aged 6 months to 4 years.

During the 2022-2023 flu season in the United States, around 21,401 people died from influenza. The vast majority of deaths due to influenza occur among the elderly, with those aged 65 years and older accounting for 15,399 deaths during the 2022-2023 flu season. During this time, the mortality rate from influenza among those aged 65 years and older was around 26.6 per 100,000 population, compared to a mortality rate of .7 per 100,000 population among those aged 18 to 49 years. Influenza deaths Although most people recover from influenza without the need of medical care, influenza and pneumonia are still major causes of death in the United States. Influenza is a common cause of pneumonia and cases in which influenza develops into pneumonia tend to be more severe and more deadly. However, the impact of influenza varies from year to year depending on which viruses are circulating. For example, during the 2017-2018 flu season around 51,000 people died due to influenza, whereas in 2022-2023 total deaths amounted to 21,000. Preventing death The most effective way to prevent influenza is to receive a yearly influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Each year, flu vaccinations prevent thousands of influenza cases, hospitalizations and deaths. It was estimated that during the 2022-2023 flu season, vaccinations prevented the deaths of around 2,479 people aged 65 years and older.

The mortality rate from influenza in the United States is by far highest among those aged 65 years and older. During the 2022-2023 flu season the mortality rate from influenza for this age group was around 26.6 per 100,000 population.

The burden of influenza The impact of influenza in the U.S. varies from season to season, but in the 2022-2023 flu season there were an estimated 31 million cases. These cases resulted in around 360,000 hospitalizations. Although most people recover from influenza without requiring medical treatment, the disease can be deadly for young children, the elderly, and those with weakened immune systems or chronic illnesses. During the 2022-2023 flu season, around 21,000 people in the U.S. lost their lives due to influenza.

Impact of vaccinations The most effective way to prevent influenza is to receive a yearly vaccination at the beginning of flu season. Flu vaccines are safe and can greatly reduce the burden of the disease. During the 2022-2023 flu season vaccinations prevented around 2,479 deaths among those aged 65 years and older. Although flu vaccines are usually cheap and easily accessible, every year a large share of the population in the U.S. still does not get vaccinated. For example, during the 2021-2022 flu season only about 37 percent of those aged 18 to 49 years received a flu vaccination.

Influenza and pneumonia caused around 12.3 deaths in the U.S. per 100,000 population in 2019. Influenza and pneumonia are among the leading causes of death in the United States, accounting for around 1.6 percent of all deaths in 2020. Influenza, or the flu, is a viral infection that is highly contagious and especially common in the winter season. Influenza is a common cause of pneumonia, although most cases of the flu do not develop into pneumonia. Pneumonia is an infection or inflammation of the lungs and is particularly deadly among young children and the elderly.

Influenza cases

Influenza is very common in the United States, with an estimated 35 million cases reported in 2019-2020. Common symptoms of the flu include cough, fever, runny or stuffy nose, sore throat and headache. Symptoms can be mild but can also be severe enough to require medical attention. In 2019-2020, there were around 16 million influenza-related medical visits in the United States.

Prevention

To prevent contracting the flu people can take everyday precautions such as regularly washing their hands and avoiding those who are sick, but the best way to prevent the flu is by receiving the flu vaccination every year. Receiving a flu vaccination is especially important for young children and the elderly as they are most susceptible to flu complications and associated death. In 2021, around 75 percent of those aged 65 years and older received a flu vaccine, while only 38 percent of those aged 18 to 49 years had done so.

Influenza, also called the flu, is one of the most infectious diseases worldwide. Its symptoms range from mild to severe, and include sore throat, cough, runny nose, fever, headache, and muscle pain, but can also cause severe illness and death among high-risk populations such as the elderly and children. During the 2022-2023 flu season, there were 31 million cases of influenza in the United States.

Influenza deaths Although influenza does not require medical attention for most people, it can be deadly, and causes thousands of deaths every year. The impact of influenza varies from year to year. The number of influenza deaths during the 2021-2022 flu season was 4,977. The vast majority of deaths attributed to influenza during the 2021-2022 flu season occurred among those aged 65 years and older.

Vaccination An annual influenza vaccination remains the most effective way of preventing influenza. During the 2021-2022 flu season, influenza vaccinations prevented an estimated 867 deaths among U.S. adults aged 65 years and older. Although, flu vaccinations are accessible and cheap, a large share of the United States population still fails to get vaccinated every year. In 2021-2022, only 37 percent of those aged 18 to 49 years received a flu vaccination, much lower compared to children and the elderly.

In 2023, the number of deaths from influenza in Japan decreased to 1383 cases, which marked an increase compared to just 24 cases in the previous year. The death rate from influenza amounted to 1.1 death cases per 100,000 inhabitants in 2023.

This statistic shows the deaths with influenza as an underlying cause in England and Wales in 2023, by age and gender. In this year, influenza was the underlying cause of 347 deaths for women aged 90 years and over.

Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

Poland Deaths: RS: ow Influenza data was reported at 431.000 Person in 2023. This records an increase from the previous number of 88.000 Person for 2022. Poland Deaths: RS: ow Influenza data is updated yearly, averaging 79.000 Person from Dec 2005 (Median) to 2023, with 19 observations. The data reached an all-time high of 431.000 Person in 2023 and a record low of 4.000 Person in 2012. Poland Deaths: RS: ow Influenza data remains active status in CEIC and is reported by Statistics Poland. The data is categorized under Global Database’s Poland – Table PL.G006: Deaths: By Cause.

WHO: Influenza A (H1N1): Number of Deaths: Mauritius data was reported at 0.000 Person in 06 Jul 2009. This stayed constant from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Mauritius data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 0.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 06 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Mauritius data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

WHO: Influenza A (H1N1): Number of Deaths: Iceland data was reported at 0.000 Person in 06 Jul 2009. This stayed constant from the previous number of 0.000 Person for 05 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Iceland data is updated daily, averaging 0.000 Person from Apr 2009 (Median) to 06 Jul 2009, with 74 observations. The data reached an all-time high of 0.000 Person in 06 Jul 2009 and a record low of 0.000 Person in 06 Jul 2009. WHO: Influenza A (H1N1): Number of Deaths: Iceland data remains active status in CEIC and is reported by World Health Organization. The data is categorized under High Frequency Database’s Disease Outbreaks – Table WHO.D002: World Heath Organization: Influenza A (H1N1): By Countries.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by sex, age group, and jurisdiction of occurrence.

Social factors have been shown to create differential burden of influenza across different geographic areas. We explored the relationship between potential aggregate-level social determinants and mortality during the 1918 influenza pandemic in Chicago using a historical dataset of 7,971 influenza and pneumonia deaths. Census tract-level social factors, including rates of illiteracy, homeownership, population, and unemployment, were assessed as predictors of pandemic mortality in Chicago. Poisson models fit with generalized estimating equations (GEEs) were used to estimate the association between social factors and the risk of influenza and pneumonia mortality. The Poisson model showed that influenza and pneumonia mortality increased, on average, by 32.2% for every 10% increase in illiteracy rate adjusted for population density, homeownership, unemployment, and age. We also found a significant association between transmissibility and population density, illiteracy, and unemployment but not homeownership. Lastly, analysis of the point locations of reported influenza and pneumonia deaths revealed fine-scale spatiotemporal clustering. This study shows that living in census tracts with higher illiteracy rates increased the risk of influenza and pneumonia mortality during the 1918 influenza pandemic in Chicago. Our observation that disparities in structural determinants of neighborhood-level health lead to disparities in influenza incidence in this pandemic suggests that disparities and their determinants should remain targets of research and control in future pandemics.

BackgroundBecause they can generate comparable predictions, mathematical models are ideal tools for evaluating alternative drug or vaccine allocation strategies. To remain credible, however, results must be consistent. Authors of a recent assessment of possible influenza vaccination strategies conclude that older children, adolescents, and young adults are the optimal targets, no matter the objective, and argue for vaccinating them. Authors of two earlier studies concluded, respectively, that optimal targets depend on objectives and cautioned against changing policy. Which should we believe?Methods and FindingsIn matrices whose elements are contacts between persons by age, the main diagonal always predominates, reflecting contacts between contemporaries. Indirect effects (e.g., impacts of vaccinating one group on morbidity or mortality in others) result from off-diagonal elements. Mixing matrices based on periods in proximity with others have greater sub- and super-diagonals, reflecting contacts between parents and children, and other off-diagonal elements (reflecting, e.g., age-independent contacts among co-workers), than those based on face-to-face conversations. To assess the impact of targeted vaccination, we used a time-usage study's mixing matrix and allowed vaccine efficacy to vary with age. And we derived mortality rates either by dividing observed deaths attributed to pneumonia and influenza by average annual cases from a demographically-realistic SEIRS model or by multiplying those rates by ratios of (versus adding to them differences between) pandemic and pre-pandemic mortalities.ConclusionsIn our simulations, vaccinating older children, adolescents, and young adults averts the most cases, but vaccinating either younger children and older adults or young adults averts the most deaths, depending on the age distribution of mortality. These results are consistent with those of the earlier studies.

Influenza viruses infect millions of humans every year causing an estimated 400,000 deaths globally. Due to continuous virus evolution current vaccines provide only limited protection against the flu. Several antiviral drugs are available to treat influenza infection, and one of the most commonly used drugs is oseltamivir (Tamiflu). While the mechanism of action of oseltamivir as a neuraminidase inhibitor is well-understood, the impact of oseltamivir on influenza virus dynamics in humans has been controversial. Many clinical trials with oseltamivir have been done by pharmaceutical companies such as Roche but the results of these trials until recently have been provided as summary reports or papers. Typically, such reports included median virus shedding curves for placebo and drug-treated influenza virus infected volunteers often indicating high efficacy of the early treatment. However, median shedding curves may be not accurately representing drug impact in individual volunteers. Importantly, due to public pressure clinical trials data testing oseltamivir efficacy has been recently released in the form of redacted PDF documents. We digitized and re-analyzed experimental data on influenza virus shedding in human volunteers from three previously published trials: on influenza A (1 trial) or B viruses (2 trials). Given that not all volunteers exposed to influenza viruses actually start virus shedding we found that impact of oseltamivir on the virus shedding dynamics was dependent on (i) selection of volunteers that were infected with the virus, and (ii) the detection limit in the measurement assay; both of these details were not well-articulated in the published studies. By assuming that any non-zero viral measurement is above the limit of detection we could match previously published data on median influenza A virus (flu A study) shedding but not on influenza B virus shedding (flu B study B) in human volunteers. Additional analyses confirmed that oseltamivir had an impact on the duration of shedding and overall shedding (defined as area under the curve) but this result varied by the trial. Interestingly, treatment had no impact on the rates at which shedding increased or declined with time in individual volunteers. Additional analyses showed that oseltamivir impacted the kinetics of the end of viral shedding, and in about 20–40% of volunteers that shed the virus treatment had no impact on viral shedding duration. Our results suggest an unusual impact of oseltamivir on influenza viruses shedding kinetics and caution about the use of published median data or data from a few individuals for inferences. Furthermore, we call for the need to publish raw data from critical clinical trials that can be independently analyzed.

There were 1,267 influenza deaths in Germany in 2023. This was a decrease compared to the year before. During the specified timeline, figures peaked in 2018, at more than three thousand deaths due to influenza.